ALTK & DSAEK offer fast visual recovery

Article

Automated lamellar therapeutic keratoplasty (ALTK) and Descemet stripping automated endothelial keratoplasty (DSAEK) are both safe and effective techniques for corneal transplantation.

Automated lamellar therapeutic keratoplasty (ALTK) and Descemet stripping automated endothelial keratoplasty (DSAEK) are both safe and effective techniques for corneal transplantation, according to Paolo Garimoldi and colleagues from Ospedale di Circolo, Italy.

Twenty eyes, 18 affected by keratocone and 2 by stromal opacity for herpes simplex keratitis, underwent ALTK. In eyes with keratocone, releasing penetrating stromal incisions were performed and a thicker graft obtained from a donor cornea, which was transplanted. The 18 eyes affected by Fuchs endothelial dystrophy underwent DSAEK; after removing the endothelium and Descemet membrane, a graft of deep stroma and endothelium from the donor cornea was inserted in the anterior chamber and positioned with an air-bubble.

Eyes treated with ALTK demonstrated very good graft transparency and an excellent quality of interface. No rejection reactions were noted and early temporary de-epithelialization occurred in 20% of cases. Best corrected visual acuity (BCVA) was 0.6 or better in 90% of subjects after three months follow-up. The eyes treated with DSAEK demonstrated a progressive increase of corneal transparency and the BCVA was 0.5 or better in 70% of cases after three months follow-up.

It was concluded that both procedures are safe and effective, particularly with regards the fast visual recovery and low level of complications.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.